(In thousands, except per-share amounts)

Company Symbol/ Revenues / Profits Per share R & D Cash Shares Period % change Current/comp Current/comp % Change or Equiv.Human Genome Sciences HGSI/1Q 12,500/1150% 4,027/(2,041) 0.26 /(0.19) 6,255 /175% 72,276 15,578Celtrix CTRX/4Q 271 /-13% (4,692)/(9,005) (0.39)/(1.08) 4,305 /-9% 26,950 11,957Aprogenex APG/1Q 0 /N/A (1,491)/(708) (0.32)/(0.23) 901 /129% 7,284 4,635Alpha-Beta Technology ABTI/1Q 506 /140% (4,271)/(3,009) (0.37)/(0.33) 3,636 /59% 57,393 11,596Viagene VIGN/1Q 3,362/48% (1,505)/(1,416) (0.14)/(0.21) NA/NA 37,795 38,314AutoImmune AIMM/1Q 0 /-100% (2,758)/(1,441) (0.27)/(0.19) 2,599 /78% 26,910 10,195Protein Design Labs PDLI/1Q 3,056/228% (1,185)/(2,135) (0.09)/(0.17) 3,360 /38% 71,027 13,932BioSurface Technology BRSF/1Q 1,008/-43% (2,585)/(1,316) (0.30)/(0.22) 2,052 /40% 22,538 8,723Cortech CRTQ/1Q 792 /-57% (5,712)/(1,344) (0.33)/(0.09) 5,034 /91% 57,223 17,426Synergen SYGN/1Q 5,743 /-39% (19,829)/(23,240) (0.77)/(0.92) 20,679 /-17% 55,824 25,717Gensia GNSA/1Q 15,895/81% (16,870)/(11,262) (0.64)/(0.40) 18,140 /63% 60,200 28,751Cambridge NeuroScience CNSI/1Q 103/* (3,731)/(3,639) (0.43)/(0.42) 3,231 /10% 3,842 8,639Cytotherapeutics CTII/1Q 1,503 /326% (2,684)/(3,393) (0.26)/(0.42) 3,151/11% 8,781 10,490Isis ISIP/1Q 5,746 /110% (1,665)/(5,052) (0.09)/(0.34) 5,825/-8% 55,900 19,080Arris Pharmaceutical ARRS/1Q 1,777 /* (1,963)/(2,059) (0.23)/(0.39) 2,993/79% 23,240 8,517ImmuLogic IMUL/1Q 5,000 /-24% (2,320)/297 (0.16)/0.02 6,340 /18% NA 14,774Mycogen MYCO/1Q 54,773 /-1% 11,423 /3,015 0.58 /0.15 4,252 /-19% 38,056 19,036Immune Response IMNR/1Q 1,240 /11% (4,632)/(3,875) (0.28)/(0.23) 3,322 /9% 71,503 16,568Genelabs GNLB/1Q 3,798 /78% (3,819)/(6,904) (0.18)/(0.36) 3,565 /19% 10,400 21,646Biogen BGEN/1Q 44,780 /26% 11,229 /11,260 (0.31)/(0.32) 23,334 /56% NA 35,741Xoma XOMA/1Q 177 /-40% (8,254)/(7,257) (0.38)/(0.34) NA/NA 62,800 21,476Cell Genesys CEGE/1Q 3,876 /230% (1,628)/(1,709) (0.12)/(0.20) 4,906 /94% 83,300 13,512NeoRx NERX/1Q 45 /-94% (2,968)/(1,986) (0.27)/(0.29) 1,757/-1% 24,776 11,543CytRx CYTR/1Q 613 /-62% (1,655)/23 (0.05)/0.00 1,606/92% 39,402 31,545LifeCell LIFC/1Q 167/43% (1,004)/(874) (0.23)/(0.20) 655/24% 4,499 4,284Applied Immune Science AISX/1Q 212/58% (8,252)/(6,216) (0.72)/(0.61) 5,176/1% 36,507 11,477Vertex Pharmaceuticals VRTX/1Q 5,632/344% (3,247)/(3,298) (0.22)/(0.27) 7,600/103% 104,993 14,746Amylin Pharmaceuticals AMLN/1Q 501/-29% (6,179)/(4,836) (0.31)/(0.28) 5,636/26% 50,100 19,709Argus Pharmaceuticals ARGS/1Q 162/170% (2,108)/(1,468) (0.21)/(0.22) 1,648/43% 17,009 10,254Bio-Technology General** BTGC/1Q 5,681/248% (782)/(3,247) 0.02 /(0.09) 3,528/13% NA 39,135SPI Pharmaceuticals SPI/1Q 72,167/-40% 8,364 /5,736 0.41 /0.29 NA/NA NA 20,588Cytogen CYTO/1Q 259/-94% (6,713)/(5,830) (0.29)/(0.28) NA/NA 25,514 22,803Aramed ARAM/1Q 352 /-20% (2,325)/(1,114) (0.81)/(0.39) 2,496 /88% 38,389 2,875Genetics Institute GENIZ/1Q 26,950 /7% (10,051)/(2,202) (0.38)/(0.14) 27,124 /14% 286,072 26,335BioCryst BCRX/1Q 93 /26% (1,564)/(1,062) (0.35)/(0.32) 1,108 /36% 6,664 4,457Glyko Biomedical GLYK/1Q 133 /600% (837)/(761) (0.09)/(0.09) NA/NA NA NAVical VICL/1Q 961 /-74% (1,302)/(1,904) (0.10)/0.21 1,866 /32% 30,400 12,828Neozyme II NIIUF/1Q 704 /-26% (3,660)/(2,027) (1.52)/(0.84) 4,310 /50% 15,831 2,415TheraTech THRT/1Q 517 /-28% (3,129)/(1,750) (0.26)/(0.17) 2,599 /35% 36,134 11,838Centocor*** CNTO/1Q 15,273 /2% (50,637)/(25,529) (1.13)/(0.62) 14,389 /-23% 168,116 44,783

All NASDAQ except Aprogenex (ASE), SPI Pharmaceuticals (AME)and Glyko (OTC)NA = Not available* Zero revenue in the first quarter of 1993** Numbers reflect extraordinary gain of $1.5 million from a debtforgiveness*** Numbers include $37 million special charge for acquired researchand development

(c) 1997 American Health Consultants. All rights reserved.